Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Β3-adrenoreceptor As Prognostic Marker in Neuroblastoma and Ewing Sarcoma

NCT06851221 is registered in ClinicalTrials.gov with Meyer Children's Hospital IRCCS as lead sponsor.

NCT NCT06851221
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06851221 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Β3-adrenoreceptor As Prognostic Marker in Neuroblastoma and Ewing Sarcoma
Lead sponsor
Meyer Children's Hospital IRCCS
Phase
Not applicable
Overall status
Completed
Start date
August 5, 2020
Completion date
March 5, 2024
Enrollment
95 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

ewing sarcoma, neuroblastoma